Title:
【発明の名称】NK-1受容体アンタゴニストとしての(2-ベンズヒドリル-1-アザビシクロ[2.2.2]オクト-3-イル)-(5-イソプロピル-2-メトキシベンジル)-アミンクエン酸塩の結晶多形
Document Type and Number:
Japanese Patent JP2003501353
Kind Code:
A
Abstract:
Two crystalline polymorphic forms of (2-Benzhydryl-1-azo-bicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate monohydrate (the monohydrates) are Form A and Form B. The pharmaceutical composition containing at least one of these polymorphs has advantageous stability for formulation to treat acute emesis in patient receiving chemotherapy. The administration of this pharmaceutical composition is conventional oral by preferably tablet or capsule and intravenous. A method of making A and B Forms is also disclosed.
Inventors:
Masset, Stephen Sargent
Qualic, George Joseph
Rose, peter robert
Wint, Lewin Theophilus
Qualic, George Joseph
Rose, peter robert
Wint, Lewin Theophilus
Application Number:
JP2001500628A
Publication Date:
January 14, 2003
Filing Date:
May 17, 2000
Export Citation:
Assignee:
Pfizer Products Inc.
International Classes:
A61K31/435; A61K31/4375; A61P1/08; A61P25/28; A61P43/00; C07D453/02; A61K; A61P; C07D; (IPC1-7): C07D453/02; A61K31/4375; A61P1/08; A61P43/00
Attorney, Agent or Firm:
Kazuo Shamoto (5 outside)